RU2012104856A - 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS - Google Patents
3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS Download PDFInfo
- Publication number
- RU2012104856A RU2012104856A RU2012104856/04A RU2012104856A RU2012104856A RU 2012104856 A RU2012104856 A RU 2012104856A RU 2012104856/04 A RU2012104856/04 A RU 2012104856/04A RU 2012104856 A RU2012104856 A RU 2012104856A RU 2012104856 A RU2012104856 A RU 2012104856A
- Authority
- RU
- Russia
- Prior art keywords
- hydrogen
- compound according
- alkyl
- compound
- fluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
1. Соединение формулы I:где Rвыбран из -Cалкила, -Cциклоалкила, необязательно замещенного 1 или 2 атомами фтора, -Cалкенила и -Cалкинила;R-Rнезависимо выбраны из водорода, галогена, -Cалкила, -CF, -O-Cлкила, -CN, -C(O)-Cалкила, -S-Cалкила, -Cциклоалкила и -NO; или Rи Rвзяты вместе с образованием -CH=CH-CH=CH-; или Rи Rвзяты вместе с образованием -CH-CH=CH-CH-;при условии, что когда Rпредставляет этил, Rпредставляет фтор-, Rпредставляет хлор-, Rпредставляет водород, и Rпредставляет водород, то Rне представляет фтор или хлор;или его фармацевтически приемлемая соль.2. Соединение по п.1, где Rпредставляет -Cалкил, выбранный из этила, пропила, изопропила, бутила, изобутила и 3-пентила.3. Соединение по п.1, где Rпредставляет -Cциклоалкил, необязательно замещенный 1 или 2 атомами фтора, выбранный из циклопропила, циклопентила, циклогексила и 4,4-дифторциклогексила.4. Соединение по п.1, где Rпредставляет бут-3-енил.5. Соединение по п.1, где Rпредставляет проп-2-инил.6. Соединение по п.1, где Rпредставляет водород, галоген, -Cалкил, -CF, -O-Cалкил, -C(O)-Cалкил, -S-Cалкил, -C-циклоалкил или -NO.7. Соединение по п.6, где Rпредставляет водород, фтор-, хлор-, -CH, -CHCH, -CF, -O-CH, -O-CHCH, -C(O)-CH, -S-CH, циклоалкил или -NO.8. Соединение по п.1, где Rпредставляет водород, галоген, -Cалкил, -CF, -O-Cалкил или -S-Cалкил.9. Соединение по п.8, где Rпредставляет водород, фтор-, хлор-, -CH, -CF, -O-CHили -S-CH.10. Соединение по п.1, где Rпредставляет водород, галоген, -Cалкил, -CFили -O-Cалкил.11. Соединение по п.10, где Rпредставляет водород, фтор-, хлор-, -CH, -CFили -O-CH.12. Соединение по п.1, где Rпредставляет водород, галоген, -Cалкил или -O-Cалкил.13. Соединение по п.12, где Rпредставляет водород, фтор-, хлор-, -CHили -O-CH.14. Соединение по п.1, где Rпредставляет водород, галоген или -Cалкил1. A compound of formula I: wherein R is selected from —Calkyl, —Cycloalkyl optionally substituted with 1 or 2 fluorine atoms, —Calkenyl and —Calkynyl; R — R are independently selected from hydrogen, halogen, —Calkyl, —CF, —O — Cl alkyl, - CN, -C (O) -Ci-alkyl, -S-Ci-alkyl, -C-cycloalkyl and -NO; or R and R are taken together with the formation of —CH═CH — CH═CH—; or R and R are taken together to form —CH — CH═CH — CH—; provided that when R is ethyl, R is fluoro, R is chloro, R is hydrogen, and R is hydrogen, then R is not fluoro or chloro; or a pharmaceutically acceptable salt. 2. A compound according to claim 1, wherein R 1 is -C-alkyl selected from ethyl, propyl, isopropyl, butyl, isobutyl and 3-pentyl. A compound according to claim 1, wherein R4 represents -Cycloalkyl optionally substituted with 1 or 2 fluorine atoms selected from cyclopropyl, cyclopentyl, cyclohexyl and 4,4-difluorocyclohexyl. A compound according to claim 1, wherein R1 represents but-3-enyl. The compound of claim 1, wherein R1 is prop-2-ynyl. 6. A compound according to claim 1, wherein R1 is hydrogen, halogen, —Calkyl, —CF, —O — C1-6alkyl, —C (O) —Calkyl, —S — C1-6alkyl, —C-cycloalkyl or —NO. The compound according to claim 6, where R is hydrogen, fluoro, chloro, —CH, —CHCH, —CF, —O — CH, —O — CHCH, —C (O) —CH, —S — CH, cycloalkyl or -NO.8. A compound according to claim 1, wherein R1 is hydrogen, halogen, —Calkyl, —CF, —O — C1-6alkyl or —S — C1-6alkyl. The compound of claim 8, wherein R1 is hydrogen, fluoro, chloro, —CH, —CF, —O — CH or —S — CH. A compound according to claim 1, wherein R1 is hydrogen, halogen, —Calkyl, —CF or —O — C1-6 alkyl. The compound of claim 10, wherein R1 is hydrogen, fluoro, chloro, —CH, —CF or —O — CH. A compound according to claim 1, wherein R1 is hydrogen, halogen, —Calkyl or —O — Calkyl. The compound of claim 12, wherein R1 is hydrogen, fluoro, chloro, —CH or —O — CH. The compound according to claim 1, where R represents hydrogen, halogen or -Cialkyl
Claims (31)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22507409P | 2009-07-13 | 2009-07-13 | |
US61/225,074 | 2009-07-13 | ||
PCT/US2010/041654 WO2011008666A2 (en) | 2009-07-13 | 2010-07-12 | 3-phenoxymethylpyrrolidine compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2012104856A true RU2012104856A (en) | 2013-08-20 |
RU2535669C2 RU2535669C2 (en) | 2014-12-20 |
Family
ID=43402084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012104856/04A RU2535669C2 (en) | 2009-07-13 | 2010-07-12 | 3-phenoxymethyl-pyrrolidine compounds |
Country Status (18)
Country | Link |
---|---|
US (3) | US7994209B2 (en) |
EP (1) | EP2454234B1 (en) |
JP (2) | JP5826173B2 (en) |
KR (1) | KR20120070561A (en) |
CN (2) | CN105254552A (en) |
AR (1) | AR077662A1 (en) |
AU (1) | AU2010273645B2 (en) |
CA (1) | CA2767372A1 (en) |
CL (1) | CL2012000097A1 (en) |
ES (1) | ES2675791T3 (en) |
IL (1) | IL217049A (en) |
MX (1) | MX2012000685A (en) |
NZ (1) | NZ597433A (en) |
RU (1) | RU2535669C2 (en) |
SG (1) | SG177647A1 (en) |
TW (1) | TWI450718B (en) |
WO (1) | WO2011008666A2 (en) |
ZA (1) | ZA201200093B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2434250T3 (en) | 2008-07-24 | 2013-12-16 | Theravance, Inc. | Compounds of 3- (phenoxyphenylmethyl) pyrrolidine |
AU2010273645B2 (en) * | 2009-07-13 | 2014-12-04 | Theravance Biopharma R&D Ip, Llc | 3-phenoxymethylpyrrolidine compounds |
EP2456436B1 (en) | 2009-07-21 | 2014-06-25 | Theravance, Inc. | 3-phenoxymethylpyrrolidine compounds |
CN103038211B (en) | 2010-07-09 | 2015-04-15 | 施万生物制药研发Ip有限责任公司 | Crystalline form of a 3-phenoxymethylpyrrolidine compound |
ES2533434T3 (en) * | 2010-10-11 | 2015-04-10 | Theravance Biopharma R&D Ip, Llc | Serotonin uptake inhibitors |
WO2012075239A1 (en) | 2010-12-03 | 2012-06-07 | Theravance, Inc. | Serotonin reuptake inhibitors |
CN109674759A (en) * | 2019-01-22 | 2019-04-26 | 深圳信立泰药业股份有限公司 | A kind of Dapoxetine hydrochloride pharmaceutical composition and preparation method thereof |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1203149A (en) * | 1968-06-10 | 1970-08-26 | Ici Ltd | Piperidine derivatives |
DE2549999A1 (en) * | 1975-11-07 | 1977-05-12 | Boehringer Mannheim Gmbh | PIPERIDINE DERIVATIVES AND THE PROCESS FOR THEIR PRODUCTION |
IL56369A (en) * | 1978-01-20 | 1984-05-31 | Erba Farmitalia | Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them |
US4956388A (en) * | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
DE3835291A1 (en) * | 1988-04-19 | 1989-11-02 | Bayer Ag | 1,3-DISUBSTITUTED PYRROLIDINES |
GB9324018D0 (en) * | 1993-11-23 | 1994-01-12 | Merck Sharp & Dohme | Therapeutic agents |
US6518284B2 (en) * | 1998-11-18 | 2003-02-11 | Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. | 4-substituted piperidines |
PL196996B1 (en) * | 1999-07-01 | 2008-02-29 | Upjohn Co | Application of optically pure (S,S)-reboxetine and the pharmaceutically acceptable salts thereof for drug preparation |
US20020151712A1 (en) * | 1999-09-14 | 2002-10-17 | Nan-Horng Lin | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
US7294637B2 (en) * | 2000-09-11 | 2007-11-13 | Sepracor, Inc. | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter |
US7384941B2 (en) * | 2002-08-23 | 2008-06-10 | Eli Lilly And Company | 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors |
ES2305776T3 (en) * | 2003-06-17 | 2008-11-01 | Pfizer Inc. | DERIVATIVES OF N-PIRROLIDIN-3-IL-AMIDA AS INHIBITORS OF THE RE-CAPTURE OF SEROTONINE AND NORADRENALINE. |
WO2005053831A2 (en) * | 2003-11-26 | 2005-06-16 | Cabot Corporation | Fuel reformer catalyst and absorbent materials |
KR20060121178A (en) * | 2003-12-12 | 2006-11-28 | 일라이 릴리 앤드 캄파니 | Selective norephinephrine reuptake inhibitors for the treatment of hot flashes, impulse control disorders and personality change due to a general medical condition |
US20070072859A1 (en) * | 2004-03-05 | 2007-03-29 | Eli Lilly And Company | Pharmaceutical compounds |
GB0409744D0 (en) * | 2004-04-30 | 2004-06-09 | Pfizer Ltd | Novel compounds |
EP1745029A1 (en) * | 2004-04-30 | 2007-01-24 | Warner-Lambert Company LLC | Substituted morpholine compounds for the treatment of central nervous system disorders |
US20090215857A1 (en) | 2005-09-13 | 2009-08-27 | Pfizer Products Inc. | Therapeutic Pyrrolidines |
EP1854785A1 (en) * | 2006-05-12 | 2007-11-14 | Faes Farma, S.A. | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions |
WO2008023258A1 (en) * | 2006-08-23 | 2008-02-28 | Pfizer Products Inc. | Piperidine derivatives |
ES2434250T3 (en) * | 2008-07-24 | 2013-12-16 | Theravance, Inc. | Compounds of 3- (phenoxyphenylmethyl) pyrrolidine |
AR075988A1 (en) * | 2009-04-09 | 2011-05-11 | Lilly Co Eli | PIRIDYLOXI COMPOUND - PIRROLIDINE INHIBITOR OF RECOVERY OF SEROTONINE AND NOREPINEFRINE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC PAIN |
WO2010120910A1 (en) * | 2009-04-15 | 2010-10-21 | Theravance, Inc. | 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds |
AU2010273645B2 (en) * | 2009-07-13 | 2014-12-04 | Theravance Biopharma R&D Ip, Llc | 3-phenoxymethylpyrrolidine compounds |
EP2456436B1 (en) | 2009-07-21 | 2014-06-25 | Theravance, Inc. | 3-phenoxymethylpyrrolidine compounds |
CN103038211B (en) * | 2010-07-09 | 2015-04-15 | 施万生物制药研发Ip有限责任公司 | Crystalline form of a 3-phenoxymethylpyrrolidine compound |
-
2010
- 2010-07-12 AU AU2010273645A patent/AU2010273645B2/en not_active Ceased
- 2010-07-12 CN CN201510846397.0A patent/CN105254552A/en active Pending
- 2010-07-12 SG SG2012002549A patent/SG177647A1/en unknown
- 2010-07-12 JP JP2012520692A patent/JP5826173B2/en not_active Expired - Fee Related
- 2010-07-12 CN CN2010800318921A patent/CN102471258A/en active Pending
- 2010-07-12 RU RU2012104856/04A patent/RU2535669C2/en not_active IP Right Cessation
- 2010-07-12 EP EP10732609.2A patent/EP2454234B1/en not_active Not-in-force
- 2010-07-12 WO PCT/US2010/041654 patent/WO2011008666A2/en active Application Filing
- 2010-07-12 KR KR20127003817A patent/KR20120070561A/en not_active Application Discontinuation
- 2010-07-12 US US12/834,128 patent/US7994209B2/en not_active Expired - Fee Related
- 2010-07-12 MX MX2012000685A patent/MX2012000685A/en active IP Right Grant
- 2010-07-12 CA CA2767372A patent/CA2767372A1/en not_active Abandoned
- 2010-07-12 ES ES10732609.2T patent/ES2675791T3/en active Active
- 2010-07-12 NZ NZ59743310A patent/NZ597433A/en not_active IP Right Cessation
- 2010-07-13 TW TW99123027A patent/TWI450718B/en not_active IP Right Cessation
- 2010-07-13 AR ARP100102536 patent/AR077662A1/en unknown
-
2011
- 2011-06-30 US US13/173,515 patent/US20110257243A1/en not_active Abandoned
- 2011-12-18 IL IL217049A patent/IL217049A/en not_active IP Right Cessation
-
2012
- 2012-01-05 ZA ZA2012/00093A patent/ZA201200093B/en unknown
- 2012-01-12 CL CL2012000097A patent/CL2012000097A1/en unknown
-
2014
- 2014-08-18 JP JP2014165783A patent/JP2014218519A/en active Pending
-
2015
- 2015-01-12 US US14/594,382 patent/US9227933B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2012532930A (en) | 2012-12-20 |
EP2454234A2 (en) | 2012-05-23 |
AR077662A1 (en) | 2011-09-14 |
JP2014218519A (en) | 2014-11-20 |
US20110257243A1 (en) | 2011-10-20 |
TWI450718B (en) | 2014-09-01 |
US7994209B2 (en) | 2011-08-09 |
CL2012000097A1 (en) | 2012-08-10 |
KR20120070561A (en) | 2012-06-29 |
ZA201200093B (en) | 2012-09-26 |
US9227933B2 (en) | 2016-01-05 |
AU2010273645A1 (en) | 2012-02-02 |
EP2454234B1 (en) | 2018-04-11 |
TW201106948A (en) | 2011-03-01 |
WO2011008666A2 (en) | 2011-01-20 |
CN102471258A (en) | 2012-05-23 |
SG177647A1 (en) | 2012-02-28 |
IL217049A0 (en) | 2012-02-29 |
JP5826173B2 (en) | 2015-12-02 |
ES2675791T3 (en) | 2018-07-12 |
MX2012000685A (en) | 2012-02-28 |
IL217049A (en) | 2015-03-31 |
RU2535669C2 (en) | 2014-12-20 |
CN105254552A (en) | 2016-01-20 |
WO2011008666A3 (en) | 2011-03-10 |
AU2010273645B2 (en) | 2014-12-04 |
CA2767372A1 (en) | 2011-01-20 |
US20150126577A1 (en) | 2015-05-07 |
US20110009465A1 (en) | 2011-01-13 |
NZ597433A (en) | 2013-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2012104856A (en) | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | |
RU2430913C2 (en) | Cycloalkylamines as monoamine reuptake inhibitors | |
RU2018145009A (en) | DERIVATIVES OF BENZYLPHENYL ETHER, METHOD FOR ITS PRODUCTION AND ITS PHARMACEUTICAL COMPOSITION AND APPLICATION | |
RU2009102278A (en) | S1P RECEPTOR MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
RU2015143672A (en) | ORGANIC COMPOUNDS | |
BRPI0413533A (en) | malonamide derivatives that block gamma secretase activity | |
RU2005123802A (en) | ADAMANTANE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS | |
MA42341A1 (en) | Protein kinase inhibitor, process for its preparation and medical use | |
JP2013010792A5 (en) | ||
JP2006501295A5 (en) | ||
JP2011529069A5 (en) | ||
RU2009128062A (en) | Compounds of the agonists and antagonists of the receptor of sphingosine-1-phosphate | |
JP2007508360A5 (en) | ||
PE20070247A1 (en) | DIMETHYLAMINE DERIVATIVES AS INHIBITING AGENTS OF DOUBLE RECAPTATION OF SEROTONIN AND NOREPINEPHRINE WITH HIGH SELECTIVITY | |
RU2006107534A (en) | COMBINATION INCLUDING ALPHA-2-DELTA-LIGAND AND AND SSRI AND / OR SNRI FOR THE TREATMENT OF DEPRESSION AND ANXIETY DISORDER | |
JP2014502974A5 (en) | ||
RU2014145819A (en) | BICYCLE CONNECTION | |
RU2010120799A (en) | COMPOUNDS FOR USE IN VISUALIZATION, DIAGNOSTICS AND / OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR TUMORS | |
WO2010011811A4 (en) | 3-(phenoxyphenylmethyl)pyrrolidine compounds | |
RU2012120759A (en) | NEW COMPOSITIONS FOR PREVENTING AND / OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | |
EA201590406A1 (en) | URECULAR AND AMIDIC DERIVATIVES OF AMINO-ALKYLPIPERASINES AND THEIR USE | |
RU2008148941A (en) | 4 - [(3-fluorophenoxy) phenylmethyl] piperidine methanesulfonate, USE, SYNTHESIS METHOD AND PHARMACEUTICAL COMPOSITIONS | |
AU2013253409A1 (en) | Analgesic | |
BRPI0416564A (en) | New prostamides for the treatment of glaucoma and related diseases | |
RU2010141964A (en) | DOPAMINE NEURO TRANSMISSION MODULATORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20160713 |